Press releases
GeNeuro SA announces the liquidation of its French subsidiary GeNeuro Innovation SAS
Geneva, Switzerland, 16 July 2025 – 8:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Lyon Economic Activities Court has pronounced on July 15, 2025, the liquidation of GeNeuro Innovation SAS, the sole subsidiary of GeNeuro SA.
This decision follows the opening on June 11, 2025, of receivership proceedings for GeNeuro Innovation SAS. The Court appointed SELARL MJ-Synergie as liquidator. This is part of the restructuring process of the GeNeuro Group, which announced on May 27 that it had obtained a definitive debt-restructuring moratorium until September 28, 2025, in Switzerland for its parent company, GeNeuro SA, a moratorium which is not affected by the receivership of its subsidiary.
About GeNeuro
- GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland.
- For more information, visit: www.geneuro.com
GeNeuro Announces Approval of all Resolutions Proposed at Extraordinary General Meeting
69.1% of the Company’s share capital was represented at the EGM and resolutions were all unanimously approved
Geneva, Switzerland, June 30, 2025 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of 30 June 2025.
69.1% of the Company’s share capital was present or represented at the EGM and resolutions were all unanimously approved. Detailed results will be available on the Company’s website at: http://www.geneuro.com/en/investors/general-meetings.
As mentioned in the invitation to the EGM, in order to ensure continuity of governance, this Extraordinary General Meeting had been called to vote on the re-election of the members of the Board of Directors, the Chairman of the Board of Directors and the Remuneration Committee, as well as the independent representative, until the next Ordinary General Meeting can be held. Following his re-election to the Board, Mr Jesús Martin-Garcia has been named Executive Chairman of the Company.
As previously announced, following the disappointing results of its last Phase 2 clinical trial in Long COVID, the Company has launched a major restructuring, making redundant all employees at the parent company level, seeking and obtaining a debt-restructuring moratorium and launching a major effort to monetize its assets. Despite the end of their employment contract at the end of December 2024, both Jesús Martin-Garcia and Mr Miguel Payró have agreed to continue on a part-time basis to support the Company’s efforts as Executive Chairman and Chief Financial Officer respectively. As for the 2024 financial statements, in view of the uncertainty surrounding the outcome of the asset monetization process, the Company had announced that it suspended publication of its financial statements.
GeNeuro SA announces the opening of receivership proceedings for its French subsidiary GeNeuro Innovation SAS
Geneva, Switzerland, 12 June 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that, at the company’s request, the Lyon Economic Activities Court decided on June 11, 2025 to open receivership proceedings against GeNeuro Innovation SAS, the sole subsidiary of GeNeuro SA.
Due to its own financial difficulties, GeNeuro Innovation SAS was obliged to place itself under the protection of the Lyon Commercial Court. The Court appointed SELARL FHBX as receiver.
This decision is part of the restructuring process of the GeNeuro Group, which announced on May 27 that it had obtained a definitive debt-restructuring moratorium in Switzerland for its parent company, GeNeuro SA, a moratorium which is not affected by the receivership of its subsidiary.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.
Contacts GeNeuro
| Jesús Martin-Garcia |
| Chairman and CEO |
| investors@geneuro.com |
GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025
Geneva, Switzerland, 10 June 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders’ meeting on June 30, 2025.
As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva Tribunal of First Instance on 26 May 2025. In this context, the Company is not in a position to finalize and present its audited annual accounts for the financial year ending 31 December 2024. Consequently, it cannot hold its Ordinary Annual General Meeting within six months of year-end, as required under Swiss corporate law.
Pursuant to the Company’s Articles of Association and applicable Swiss legal provisions, the mandates of the current members of the Board of Directors will expire on 30 June 2025. To ensure continuity of governance, the Extraordinary General Meeting has been convened to vote on the re-election of the Board members, of the Chairman, of the Remuneration Committee, and of the Independent Proxy until the next Annual General Meeting can be held.
The notice to the meeting is published today in the Swiss Official Gazette of Commerce.
Contacts GeNeuro
| Jesús Martin-Garcia |
| Chairman and CEO |
| investors@geneuro.com |
GeNeuro SA Announces Definitive Debt-Restructuring Moratorium
Geneva, Switzerland, 27 May 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a May 26, 2025, judgment, granted GeNeuro SA a four-month definitive debt-restructuring moratorium, under the continued supervision of the court-appointed commissary.
French Press release
GeNeuro SA announces the postponement of the publication of the Company’s 2024 annual results
Geneva, Switzerland, 12 May 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of the publication of its December 31, 2024 annual results and annual financial report in order to be able to take into account the financial impacts of the restructuring targeted by the Company as part of the granted debt-restructuring moratorium procedure. The Company will announce by press release the new date of their approval and publication.
Français: